What does FDA's proposed DTC advertising rule mean for pharma?
For decades, direct-to-consumer (DTC) advertising has been a defining feature of the US healthcare system. Across the nation, millions of Americans have grown accustomed to television commercials encouraging them to “ask your doctor” about a particular prescription medicine, alongside a roll call of the drug's most significant risks and directions on where to find more detailed safety information.
But, if the Trump administration has its way, that familiar formula could soon disappear.
Last month, the US Food and Drug Administration (FDA) quietly added a proposed rule to the 2026 Unified Agenda that – if finalised – could make prescription drug adverts untenable.
The proposal is just the latest effort in a broader campaign to tighten oversight of prescription drug advertising.
"I got a call from an old friend right after the federal elections in 2025," recalls Jim Potter, executive director of the Coalition for Healthcare Communication. "He said, 'You need to know they're lining up all the campaign issues and promises, and they're dedicating teams to them.'"
For Potter, the conversation confirmed what he had already suspected. Following President Donald Trump's memorandum calling on the Department of Health and Human Services (HHS) and the FDA to address what the administration described as “deceptive” or “incomplete risk information” in prescription drug advertising, greater scrutiny of DTC marketing seemed inevitable.
What changes to DTC advertising is the FDA proposing?
At the heart of the Administration’s proposal is a concept known as “adequate provisions”. Introduced back in 1997, this framework has allowed pharma companies to truncate a drug's rather lengthy safety information into bite-sized “major statements” during broadcast commercials, provided the advert also directed viewers to additional resources, such as a URL or toll-free phone number, where the complete safety information could be found.
For pharma companies, this change made broadcast advertising a feasible reality as major statements could fit the average 30-90 second advertising slots. But, according to Health and Human Services Secretary Robert F. Kennedy, Jr. and HHS, the provisions are a “loophole” that “denies patients vital safety information required for them to make an informed decision”.
"Pharmaceutical ads hooked this country on prescription drugs," Kennedy said when the proposal was first announced back in September. "We will shut down that pipeline of deception and require drug companies to disclose all critical safety facts in their advertising. Only radical transparency will break the cycle of overmedicalisation that drives America's chronic disease epidemic."
Essentially, the Administration intends to return the industry to the pre-1997 standard, removing the adequate provisions option and instead forcing pharma companies to include every clinically relevant warning within the broadcast commercial, a move that would dramatically push the length of adverts well beyond the industry standard of 30-90 seconds.
Although the Administration insists that this is not an overt ban on DTC advertising, both the HHS and FDA have acknowledged that requiring TV ads to run a complete safety profile for a drug would make broadcast advertising “prohibitively long and expensive”. But, by making it difficult, if not impossible, for companies to feasibly meet both the conditions of both the FDA and advertisers, critics argue that this proposal is the Administration’s way of side-stepping potential constitutional challenges. In essence, they say, it constitutes a de facto ban.
What does this mean for pharma?
As Potter sees it, this has been writing on the wall since the plan was first announced last year. Both President Trump and RFK Jr have been calling for DTC reform since before either officially entered office. Prescription drug ads are a contentious topic in the US, attracting vocal critics across both sides of the political spectrum, and TV is where the FDA has the most regulatory authority.
Cautious that Executive Orders may be on the horizon, as had been the case during the Administration's first term, Potter and his legal team quickly got to work boning up on court precedents, FDA history, and legislative history in the US.
“That painted a pretty good picture,” he says. “Advertising is essentially a form of commercial speech, according to precedents set in the 1970s and 80s. Banning that violates the First Amendment.”
But, despite the attention surrounding the announcement, he cautions against treating the proposal as though it were settled policy. The FDA's rulemaking process is a long and complicated process, with multiple rounds of consultation, revisions, and the publication of a final rule before any new requirements take effect. Even then, he notes, there is strong precedent for legal challenges to delay implementation further.
What’s more, Potter argues, is that many companies have navigated this type of regulatory uncertainty before, in what he calls the FDA “gotcha game”.
“There was a lot of confusion on what this term adequate provision meant,” he says, in reference to the period before adequate provisions guidance was published in 1997. “And so essentially what was happening is that someone would come up with a new prescription drug advertisement, and the FDA would say, “No. Gotcha!”
“We've seen that repeated this past year, in September, when they started sending out warning letters,” he continues.
So, should the industry be concerned? Not just yet, says Potter.
"Unless it's a law passed and implemented in rules, or rules that are enforceable and haven't been challenged legally, don't change your behaviour," he says.
However, that does not mean companies should ignore the proposal altogether.
Instead, Potter believes organisations should use the consultation period to understand the potential commercial implications of the rule, quantify its business impact and prepare detailed responses once the FDA publishes its Notice of Proposed Rulemaking (NPRM). Those arguments, he says, could prove valuable both during the consultation process and in any subsequent legal proceedings.
John Kenny, chief strategy officer at EVERSANA, agrees that companies should avoid making knee-jerk decisions, but believes the proposal nevertheless offers a glimpse of where pharma communications are heading.
"I think the industry is getting prepared," he says. "There will, more than likely, be a fight about this in 2027, but how it gets resolved is anyone's guess."
Why pharma is bracing for a legal battle
One of the core challenges at the heart of the DTC prescription drug advertising debate can be distilled into one simple question: What are these adverts designed to do?
While the Administration may argue that the industry is using the adequate provisions clause to hide information, for those on the other side of the debate, education is the whole point.
As Kenny explains, “Most Americans don't want their only advice for medical communication coming from an employee of an insurance company. They've always enjoyed access to a free market of information. That's unique to the US.”
He continues: “What pharmaceutical advertising more than anything does is get people to talk to their doctor about a condition that they've given up on. And that's something I think everyone in the industry should feel really proud of.”
This right to access information that may instrumental. At the heart of the debate is the First Amendment, which protects commercial speech under decades of US legal precedent.
"Advertising is essentially a form of commercial speech," Potter says. "Banning that violates the First Amendment."
Potter points to the Central Hudson test, established by the Supreme Court in 1980, as the framework courts use when determining whether restrictions on commercial advertising are constitutionally permissible.
Under the Central Hudson test, the government must demonstrate not only that it is pursuing a substantial public interest, but also that any restrictions on commercial speech are appropriately tailored and no more burdensome than necessary. Potter argues that previous administrations have generally sought less restrictive ways of regulating pharmaceutical advertising, rather than attempting to prohibit it outright.
Whether the FDA's proposal crosses that constitutional line is likely to become one of the defining questions of any legal challenge.
Moreover, the pharma industry is unlikely to stand alone in any upcoming legal fight. Television broadcasters and advertising agencies have significant commercial interests tied to prescription drug advertising, making them likely allies should the proposal move forward.
"There are a lot of interested parties, not just from the pharma industry, but from the media industry," Kenny says. "Pharma is the number two source of advertising for TV companies."
Even so, neither Potter nor Kenny is prepared to predict the outcome.
"There is a lot of precedent to support the pharma industry," Kenny says. "The challenge is we've seen precedent be overturned by the current judiciary leadership of the Supreme Court. So there's just a lot of uncertainty about what will actually happen."
For now, that uncertainty defines the industry's response. Pharmaceutical companies may not yet be rewriting their advertising campaigns, but many are already preparing for what could become one of the most closely watched legal battles over direct-to-consumer advertising in decades.
Will this affect other advertising media?
Of course, TV ads only account for a portion of today’s advertising spend. Increasingly, digital channels are being used to disseminate information, as they allow for more frequent, targeted campaigns. As such, Potter and Kenny predict that the implications of this current challenge will extend well beyond broadcast media. Whether or not the rule ultimately survives, they argue it signals a broader shift in how regulators are approaching pharmaceutical communications.
For Kenny, the significance of the proposal extends beyond a single television advertising rule. It reflects an administration that is becoming increasingly willing to challenge long-established approaches to pharmaceutical promotion, prompting companies to think more broadly about how they engage patients.
"I think pharma needs to radically rethink the role of unbranded, the role of digital therapeutics, building one-to-one relationships with patients, and really dialling up their communication with HCP," he says.
In that sense, the proposal is not simply a question of whether 30-second television commercials survive in their current form. It is another signal that pharmaceutical companies may need to diversify how they communicate with patients, relying less heavily on traditional broadcast advertising and investing more in channels that support longer, more personalised conversations.
Whether that transition is driven by regulation, changing media habits or both remains to be seen. But for Kenny, one thing is clear.
"I don't think this is just about television," he says. "I think they will go after all channels."
